Drugs / Hyperpolarized 13C-Pyruvate
Hyperpolarized 13C-Pyruvate
Trials 26 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03685175 | Jul 2018 → Feb 2025 | breast cancer | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT02526368 | Mar 2016 → Dec 2026 expected | prostate carcinoma | Ivan de Kouchkovsky, MD | Recruiting | No outcome recorded |
| Phase 115 trials | ||||||
| Phase 1 | NCT05866679 | Apr 2024 → Aug 2026 | ovarian cancer | M.D. Anderson Cancer Center | Suspended | No outcome recorded |
| Phase 1 | NCT06103201 | Oct 2023 → Nov 2026 expected | subarachnoid hemorrhage, traumatic brain injury | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 1 | NCT06014905 | Sep 2023 → Sep 2027 expected | meningioma | Javier Villaneuva-Meyer, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT05873699 | Aug 2023 → Jan 2027 expected | cystic tumor of the pancreas | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05041166 | Sep 2021 → Sep 2026 expected | — | Memorial Sloan Kettering Cancer Center | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT04656431 | Jun 2021 → Mar 2027 expected | primary central nervous system lymphoma | James Rubenstein | Recruiting | No outcome recorded |
| Phase 1 | NCT04589624 | Aug 2020 → May 2027 expected | thyroid gland carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04772456 | Aug 2020 → Aug 2026 overdue | glioma | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 1 | NCT04019002 | Nov 2019 → Sep 2025 | glioblastoma | Susan Chang | Completed | No outcome recorded |
| Phase 1 | NCT03830151 | May 2019 → Dec 2028 expected | primary brain neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03565367 | Nov 2018 → Jun 2019 | central nervous system cancer | Daniel M. Spielman | Completed | No outcome recorded |
| Phase 1 | NCT04540107 | Jan 2017 → Jan 2027 expected | grade II glioma, grade III glioma | Susan Chang | Recruiting | No outcome recorded |
| Phase 1 | NCT02911467 | Nov 2016 → Jul 2020 | prostate cancer | Rahul Aggarwal | Terminated | No outcome recorded |
| Phase 1 | NCT01807702 | Mar → Jul 2013 | — | University of Florida | Completed | No outcome recorded |
| Phase 1 | NCT01229618 | Oct 2010 → Nov 2011 | prostate cancer | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05599048 | Dec 2022 → Jan 2027 expected | neoplasm | Robert Bok, MD, PhD | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02913131 | Oct 2016 → Apr 2021 | prostate cancer | Rahul Aggarwal | Terminated | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06645691 | Oct 2024 → May 2028 expected | heart failure, metabolic syndrome X | National Heart Centre Singapore | Recruiting | No outcome recorded |
| Phase 2 | NCT04951921 | Jul 2021 → Jul 2024 | cervical cancer | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04698564 | Dec 2020 → Dec 2025 | prostate cancer | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 2 | NCT04565327 | Aug 2020 → Nov 2022 | pancreatic ductal adenocarcinoma | Zhen Wang, MD | Terminated | No outcome recorded |
| Phase 2 | NCT03581500 | Feb 2019 → Oct 2024 | prostate adenocarcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT04258462 | Jan 2019 → Oct 2026 expected | kidney benign neoplasm, renal cell carcinoma | Zhen Wang, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03933670 | Jul 2018 → Dec 2027 expected | prostate adenocarcinoma | University of California, San Francisco | Recruiting | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hyperpolarized 13C-pyruvate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06645691 ↗ |
| Known as | 13C-Pyruvate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01807702 ↗ |
| Known as | HP 13C-pyruvate | “The FDA is allowing the use of hyperpolarized \[1-13C\] pyruvate (HP 13C-pyruvate) in this study.” NCT04772456 ↗ |
| Known as | Hyperpolarized (HP) carbon^13 (13C)-pyruvate | “Hyperpolarized (HP) carbon^13 (13C)-pyruvate” NCT05599048 ↗ |
| Known as | Hyperpolarized Carbon C 13 Pyruvate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03581500 ↗ |
| Known as | Hyperpolarized pyruvate (13C) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04656431 ↗ |
| Known as | Hyperpolarized Pyruvate (13C) Injection | “Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized ("hyperpolarized") \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C...” NCT04698564 ↗1“Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized ("hyperpolarized") [13C]pyruvate, is being studied as a diagnostic agent in combination with 13C...” NCT06103201 ↗ |
| Known as | Pyruvate (13C) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02911467 ↗ |
| Modality | Diagnostic / imaging agent | “Diagnostic procedures, such as MRSI with hyperpolarized carbon (13C) pyruvate” NCT02526368 ↗ |
| Route | Intravenous | “single hyperpolarized pyruvate IV (intravenous) injection” NCT01229618 ↗ |